{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:05:38Z","timestamp":1781557538576,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s13300-020-00889-9","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T16:02:52Z","timestamp":1595606572000},"page":"1925-1934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9206-5837","authenticated-orcid":false,"given":"David M.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"issue":"1","key":"889_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","volume":"3","author":"G Savarese","year":"2017","unstructured":"Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7\u201311.","journal-title":"Card Fail Rev"},{"issue":"3","key":"889_CR2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","volume":"171","author":"C Cook","year":"2014","unstructured":"Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368\u201376.","journal-title":"Int J Cardiol"},{"issue":"1","key":"889_CR3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.15420\/cfr.2016:20:2","volume":"3","author":"GM Rosano","year":"2017","unstructured":"Rosano GM, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus. Card Fail Rev. 2017;3(1):52\u20135.","journal-title":"Card Fail Rev"},{"key":"889_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2016.07.025","volume":"182","author":"JB Echouffo-Tcheugui","year":"2016","unstructured":"Echouffo-Tcheugui JB, Xu H, DeVore AD, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get with The Guidelines-Heart Failure registry. Am Heart J. 2016;182:9\u201320.","journal-title":"Am Heart J"},{"issue":"S1","key":"889_CR5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjcard.2019.10.024","volume":"124","author":"MJ Wilkinson","year":"2019","unstructured":"Wilkinson MJ, Zadourian A, Taub PR. Heart failure and diabetes mellitus: defining the problem and exploring the interrelationship. Am J Cardiol. 2019;124(S1):S3\u2013S11.","journal-title":"Am J Cardiol"},{"issue":"5","key":"889_CR6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.cjca.2018.02.026","volume":"34","author":"P Meagher","year":"2018","unstructured":"Meagher P, Adam M, Civitarese R, Bugyei-Twum A, Connelly KA. Heart failure with preserved ejection fraction in diabetes: mechanisms and management. Can J Cardiol. 2018;34(5):632\u201343.","journal-title":"Can J Cardiol"},{"issue":"11","key":"889_CR7","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377\u201385.","journal-title":"Eur Heart J"},{"issue":"2","key":"889_CR8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10741-018-9679-y","volume":"23","author":"KO Bonsu","year":"2018","unstructured":"Bonsu KO, Arunmanakul P, Chaiyakunapruk N. Pharmacological treatments for heart failure with preserved ejection fraction\u2014a systematic review and indirect comparison. Heart Fail Rev. 2018;23(2):147\u201356.","journal-title":"Heart Fail Rev"},{"issue":"5","key":"889_CR9","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s13300-019-0657-8","volume":"10","author":"A Ali","year":"2019","unstructured":"Ali A, Bain S, Hicks D, et al. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c-translating evidence into practice. Diabetes Ther. 2019;10(5):1595\u2013622.","journal-title":"Diabetes Ther"},{"issue":"3","key":"889_CR10","doi-asserted-by":"crossref","first-page":"e014908","DOI":"10.1161\/JAHA.119.014908","volume":"9","author":"C Arnott","year":"2020","unstructured":"Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9(3):e014908.","journal-title":"J Am Heart Assoc"},{"issue":"10166","key":"889_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"key":"889_CR12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Eng J Med. 2015;373:2117\u2013288.","journal-title":"N Eng J Med"},{"issue":"7","key":"889_CR13","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"24","key":"889_CR14","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"4","key":"889_CR15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"889_CR16","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"key":"889_CR17","unstructured":"Food and Drug Administration (FDA). FDA approves new treatment for a type of heart failure. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-type-heart-failure. Accessed 10 July 2020."},{"key":"889_CR18","unstructured":"American College of Cardiology. Evaluation of ertugliflozin efficacy and safety cardiovascular outcomes trial\u2014VERTIS CV. 2020. https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2020\/06\/16\/11\/24\/vertis. Accessed 10 July 2020"},{"key":"889_CR19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ahj.2018.08.016","volume":"206","author":"CP Cannon","year":"2018","unstructured":"Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11\u201323.","journal-title":"Am Heart J"},{"key":"889_CR20","unstructured":"National Institute for Health and Care Excellence (NICE). Chronic heart failure in adults: diagnosis and management. 2018. https:\/\/www.nice.org.uk\/guidance\/ng106\/chapter\/Recommendations#treating-heart-failure-with-reduced-ejection-fraction. Accessed 10 July 2020."},{"issue":"6","key":"889_CR21","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137\u2013e161161.","journal-title":"Circulation"},{"issue":"16","key":"889_CR22","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147\u2013e239.","journal-title":"J Am Coll Cardiol"},{"key":"889_CR23","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failuree \u2013 Web Addenda: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129\u2013200.","DOI":"10.1093\/eurheartj\/ehw128"},{"issue":"4","key":"889_CR24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11883-014-0403-7","volume":"16","author":"J George","year":"2014","unstructured":"George J, Struthers AD, Lang CC. Modulation of the renin\u2013angiotensin\u2013aldosterone system in heart failure. Curr Atheroscler Rep. 2014;16(4):403.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"889_CR25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrcardio.2012.196","volume":"10","author":"CC Lang","year":"2013","unstructured":"Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol. 2013;10(3):125\u201334.","journal-title":"Nat Rev Cardiol"},{"key":"889_CR26","first-page":"CD012897","volume":"12","author":"S Safi","year":"2017","unstructured":"Safi S, Korang SK, Nielsen EE, et al. Beta-blockers for heart failure. Cochrane Database Syst Rev. 2017;12:CD012897.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"889_CR27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10741-014-9453-8","volume":"20","author":"C Bavishi","year":"2015","unstructured":"Bavishi C, Chatterjee S, Ather S, Patel D, Messerli FH. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev. 2015;20(2):193\u2013201.","journal-title":"Heart Fail Rev"},{"issue":"20","key":"889_CR28","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476\u201386.","journal-title":"J Am Coll Cardiol"},{"issue":"S1","key":"889_CR29","first-page":"A312","volume":"66","author":"D Fitchett","year":"2017","unstructured":"Fitchett D, McKnight J, Lee J, et al. Empagliflozin (EMPA) reduces heart failure irrespective of control of blood pressure (BP), low density lipoprotein cholesterol (LDL-C) and HbA1c. Diabetes. 2017;66(S1):A312\u2013A313313.","journal-title":"Diabetes"},{"issue":"10","key":"889_CR30","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317.","journal-title":"Diabetologia"},{"issue":"12","key":"889_CR31","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1111\/dom.13855","volume":"21","author":"CCJ Dekkers","year":"2019","unstructured":"Dekkers CCJ, Sj\u00f6str\u00f6m CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJL. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(12):2667\u2013733.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"889_CR32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):73.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"889_CR33","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115\u201322.","journal-title":"Diabetes Care"},{"issue":"5","key":"889_CR34","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jacbts.2018.08.002","volume":"3","author":"PA Crawford","year":"2018","unstructured":"Crawford PA. Refueling the failing heart: a case for sodium-glucose cotransporter 2 inhibition in cardiac energy homeostasis. JACC Basic Transl Sci. 2018;3(5):588\u201390.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"889_CR35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"M Packer","year":"2020","unstructured":"Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508\u201311.","journal-title":"Diabetes Care"},{"issue":"5","key":"889_CR36","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4103\/2230-8210.183826","volume":"20","author":"S Kalra","year":"2016","unstructured":"Kalra S, Jain A, Ved J, Unnikrishnan AG. Sodium-glucose cotransporter 2 inhibition and health benefits: the Robin Hood effect. Indian J Endocrinol Metab. 2016;20(5):725\u20139.","journal-title":"Indian J Endocrinol Metab"},{"issue":"3","key":"889_CR37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, Wust RC, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568\u201373.","journal-title":"Diabetologia"},{"issue":"9","key":"889_CR38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","volume":"2","author":"M Packer","year":"2017","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2(9):1025\u20139.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"889_CR39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12933-017-0564-0","volume":"16","author":"F Shigiyama","year":"2017","unstructured":"Shigiyama F, Kumashiro N, Miyagi M, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017;16(1):84.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"889_CR40","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3390\/jcm8070983","volume":"8","author":"V Lambadiari","year":"2019","unstructured":"Lambadiari V, Pavlidis G, Kousathana F, et al. Effects of different antidiabetic medications on endothelial glycocalyx, myocardial function, and vascular function in type 2 diabetic patients: one year follow-up study. J Clin Med. 2019;8(7):983.","journal-title":"J Clin Med"},{"key":"889_CR41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","volume":"104","author":"TM Lee","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298\u2013310.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"889_CR42","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.2337\/dc19-2187","volume":"43","author":"JSS Singh","year":"2020","unstructured":"Singh JSS, Mordi IR, Vickneson K, et al. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM trial. Diabetes Care. 2020;43(6):1356\u20139.","journal-title":"Diabetes Care"},{"issue":"10","key":"889_CR43","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","volume":"21","author":"M Packer","year":"2019","unstructured":"Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail. 2019;21(10):1270\u20138.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"889_CR44","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","volume":"21","author":"SD Anker","year":"2019","unstructured":"Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. 2019;21(10):1279\u201387.","journal-title":"Eur J Heart Fail"},{"key":"889_CR45","unstructured":"ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure with Reduced Ejection Fraction (EMPEROR-Reduced). 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057977. Accessed 10 July 2020"},{"key":"889_CR46","unstructured":"ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure with Preserved Ejection Fraction (EMPEROR-Preserved). 2020b. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057951. Accessed 10 July 2020"},{"issue":"2","key":"889_CR47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s13300-019-00747-3","volume":"11","author":"DM Williams","year":"2020","unstructured":"Williams DM, Nawaz A, Evans M. Renal outcomes in type 2 diabetes: a review of cardiovascular and renal outcome trials. Diabetes Ther. 2020;11(2):369\u201386.","journal-title":"Diabetes Ther"},{"issue":"12","key":"889_CR48","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/heartjnl-2018-314158","volume":"105","author":"AL Clark","year":"2019","unstructured":"Clark AL, Kalra PR, Petrie MC, Mark PB, Tomlinson LA, Tomson CR. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019;105(12):904\u201310.","journal-title":"Heart"},{"key":"889_CR49","doi-asserted-by":"crossref","unstructured":"Inzucchi SE, Docherty K, Kober L, et al. 271-OR: ADA Presidents\u2019 select abstract: effect of dapagliflozin on the incidence of diabetes: a prespecified exploratory analysis from DAPA-HF. Diabetes. 2020;69(S1):271-OR","DOI":"10.2337\/db20-271-OR"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00889-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-020-00889-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00889-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T19:54:17Z","timestamp":1696449257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-020-00889-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1007\/s13300-020-00889-9","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"assertion":[{"value":"7 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}